ANNALS OF INTERNAL MEDICINE内科学年鉴
ANNALS OF INTERNAL MEDICINE(英文缩写 ANN INTERN MED),ISSN 0003-4819,eISSN 1539-3704,中文译名:内科学年鉴 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 51.598 | Q1 |
| 2022 | 39.200 | Q1 |
| 2023 | 19.600 | Q1 |
| 2024 | 15.200 | Q1 |
| 2025 | 17.200 | Q1 |
ANNALS OF INTERNAL MEDICINE 最新收录文献
-
1. Serving Those Who Served: Tobacco Cessation for Veterans and Active-Duty Service Members.
PMID:日期:2026-09-22该文献暂无摘要。
-
2. Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
2. 烟草使用治疗：2026年美国退伍军人事务部和美国国防部临床实践指南概要PMID:日期:2026-09-22A work group representing the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) prepared a new VA/DoD clinical practice guideline (CPG) for tobacco use treatment. This article provides a synopsis of the 2026 CPG, which addresses use of commercially available tobacco and nicotine products. A multidisciplinary work group developed 19 key questions on clinical topics of highest priority for the VA and DoD populations. Published literature from 1 January 2014 to 10 December 2024 was systematically reviewed using the PICOTS (population, intervention, comparator, outcomes, timing of outcomes measurement, and setting) framework. Recommendations were made by consensus and informed by evaluation using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method, which assesses quality of evidence and balances benefits and harms, patient preferences, and feasibility. The final document incorporated input from peer review by an external group of experts. The 2026 guideline includes 32 recommendations across 10 topic areas. Key recommendations for increasing abstinence from combustible tobacco include recommending motivational interviewing to increase engagement in treatment of tobacco and nicotine use (strong) and use of U.S. Food and Drug Administration-approved pharmacotherapies (strong), with varenicline recommended over monotherapy with other agents (strong), combination nicotine replacement therapy ([NRT] for example, patch plus lozenge) recommended over NRT monotherapy (single agent) (strong), and extending use of bupropion sustained release beyond 12 weeks (weak). Other key recommendations include varenicline for increasing abstinence from smokeless tobacco (strong) and electronic nicotine delivery systems (weak) and use of NRT or varenicline to increase quit attempts and abstinence in patients not ready to quit in the next 30 days (weak).
-
4. Alcohol Use Between 2018 and 2024: A National Cross-Sectional Study.
4. 2018年至2024年间的酒精使用：一项全国性横断面研究PMID:日期:2026-09-22该文献暂无摘要。
-
6. Correction to I.M. Matters News: Wrestling with recurrent UTIs.
6. 对I.M. Matters新闻的更正：与反复发作的尿路感染作斗争PMID:日期:2026-09-15该文献暂无摘要。
-
7. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline.
7. 慢性肾脏病贫血的评估与管理：肾脏疾病：改善全球预后2026临床实践指南概要PMID:日期:2026-09-15[中文摘要] 《肾脏疾病：改善全球结局（KDIGO）2026年慢性肾脏病（CKD）贫血管理临床实践指南》提供了2012年版的更新。其范围包括贫血诊断以及铁剂治疗、促红细胞生成素刺激剂（ESAs）、缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHIs）和红细胞（RBC）输注在CKD贫血治疗中的应用。一个由患者伙伴、医疗保健专业人员、研究人员和临床医生组成的国际工作组确定了指南范围。一个独立证据审查团队通过2024年10月进行了系统评价，并使用GRADE（推荐意见评估、制定与评价分级）方法对证据确定性进行分级。最终指南纳入了2024年末注册利益相关方参与的公开审查反馈。本概要重点关注8条分级推荐意见。要点包括：使用转铁蛋白饱和度和铁蛋白阈值指导铁剂治疗，在接受血液透析的患者中静脉铁剂优于口服铁剂；在使用ESA或HIF-PHI之前纠正贫血的可纠正原因；使用ESA而非HIF-PHI作为一线治疗；根据患者特征、症状和价值观个体化确定启动ESA的血红蛋白（Hb）阈值；以及在ESA维持治疗期间Hb目标上限低于11.5 g/dL（<115 g/L）。该指南还包括49条实践要点，代表在缺乏强有力证据或无法进行系统评价的情况下的专家共识。
[英文摘要] The Kidney Disease: Improving Global Outcomes (KDIGO) 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) provides an update of the 2012 version. Its scope includes anemia diagnosis and use of iron therapy, erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs), and red blood cell (RBC) transfusions to treat anemia in CKD. An international work group of patient partners, health care professionals, researchers, and clinicians defined the guideline scope. An independent evidence review team conducted systematic reviews through October 2024 and graded the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. The final guideline incorporated feedback from a public review involving registered stakeholders in late 2024. This synopsis focuses on the 8 graded recommendations. Key points include the use of transferrin saturation and ferritin thresholds to guide iron therapy, with intravenous iron preferred over oral iron in people receiving hemodialysis; addressing correctable causes of anemia before use of an ESA or a HIF-PHI; using an ESA rather than a HIF-PHI as first-line treatment; individualized hemoglobin (Hb) thresholds for ESA initiation based on patient characteristics, symptoms, and values; and an upper Hb target of below 11.5 g/dL (<115 g/L) during ESA maintenance therapy. The guideline also includes 49 practice points representing expert consensus where robust evidence was limited or systematic review could not be conducted.
-
8. Quality Improvement at a Crossroads: Securing Its Place in Academic Medicine.
8. 十字路口的质量改进：在学术医学中确立其地位PMID:日期:2026-09-15该文献暂无摘要。
-
9. Medetomidine Exposure in a Shifting Drug Landscape: Insights From Patient Experiences.
PMID:日期:2026-09-15该文献暂无摘要。
-
10. Disclosure Without Context: The Case for More Transparent Clinical Practice Guidelines.
PMID:日期:2026-09-15该文献暂无摘要。